New drug candidate BL-B01D1 targets Hard-to-Treat cancers in early trial
NCT ID NCT05803018
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called BL-B01D1 in people with advanced gynecological cancers or other solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if the drug can shrink tumors. About 38 adults aged 18 to 75 will take part, and the study will also monitor side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GYNECOLOGICAL MALIGNANT TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University ShangHai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a new infusion drug tame advanced solid tumors?
- Can a radioactive injection target bone tumors? a Dose-Finding trial aims to find out
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Can a new drug shrink Hard-to-Treat solid tumors?